AMT-151 is under clinical development by Multitude therapeutics and currently in Phase I for Malignant Pleural Mesothelioma. According to GlobalData, Phase I drugs for Malignant Pleural Mesothelioma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AMT-151’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AMT-151 overview

AMT-151 is under development for the treatment of solid tumor including endometrial cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, pancreatic ductal adenocarcinoma, malignant pleural mesothelioma, triple-negative breast cancer (TNBC), lung adenocarcinoma, non-small cell lung cancer (NSCLC) and unspecified indication. It is administered through intravenous route.

Multitude therapeutics overview

Multitude therapeutics is a Pharmaceuticals and Healthcare company that Develop antibody-drug conjugates. The company is headquartered in Redwood city, California, The U.S.

For a complete picture of AMT-151’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.